Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes
- Author
- WAGMAN, Allan S1 ; JOHNSON, Kirk W2 ; BUSSIERE, Dirksen E3
[1] Medicinal Chemistry, Chiron Corporation, 4560 Horton Street, M/S 4.5, Emeryville, CA 94608-2916, United States
[2] Pharmacology and Preclinical Development, Genesoft Pharmaceuticals, Inc., 7300 Shoreline Ct., South San Francisco, CA 94080, United States
[3] Computational Chemistry and Structural Biology, Chiron Corporation, 4560 Horton Street, M/S 4.5, Emeryville, CA 94608-2916, United States - Issue title
- Kinase and phosphatase drug discovery and design
- Author (monograph)
- BUSSIERE, Dirksen E (Editor)1
[1] Biopharma Research, Chiron Corporation, Emeryville, CA, United States - Source
Current pharmaceutical design. 2004, Vol 10, Num 10, pp 1105-1137, 33 p ; ref : 222 ref
- ISSN
- 1381-6128
- Scientific domain
- Pharmacology drugs
- Publisher
- Bentham Science, Hilversum
- Publication country
- Netherlands
- Document type
- Article
- Language
- English
- Keyword (fr)
- Diabète type 2 Découverte Traitement Endocrinopathie
- Keyword (en)
- Type 2 diabetes Discoveries Treatment Endocrinopathy
- Keyword (es)
- Diabetes de tipo 2 Descubierta Tratamiento Endocrinopatía
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02A General pharmacology / 002B02A03 Pharmaceutical technology. Pharmaceutical industry
- Discipline
- General pharmacology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 15658924
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.2174/1381612043452668 
https://dx.doi.org/10.2174/1381612043452668
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612043452668\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:81:\"Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1105\";s:8:\"\u0000*\u0000epage\";s:4:\"1137\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WAGMAN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Allan S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:15:\"JOHNSON, Kirk W\";i:1;s:19:\"BUSSIERE, Dirksen E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:48:\"Kinase and phosphatase drug discovery and design\";s:8:\"\u0000*\u0000title\";s:81:\"Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"33\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612043452668\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:81:\"Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1105\";s:8:\"\u0000*\u0000epage\";s:4:\"1137\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WAGMAN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Allan S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:15:\"JOHNSON, Kirk W\";i:1;s:19:\"BUSSIERE, Dirksen E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:48:\"Kinase and phosphatase drug discovery and design\";s:8:\"\u0000*\u0000title\";s:81:\"Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"33\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612043452668\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612043452668\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:81:\"Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1105\";s:8:\"\u0000*\u0000epage\";s:4:\"1137\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WAGMAN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Allan S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:15:\"JOHNSON, Kirk W\";i:1;s:19:\"BUSSIERE, Dirksen E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:48:\"Kinase and phosphatase drug discovery and design\";s:8:\"\u0000*\u0000title\";s:81:\"Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"33\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612043452668\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:81:\"Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1105\";s:8:\"\u0000*\u0000epage\";s:4:\"1137\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WAGMAN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Allan S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:15:\"JOHNSON, Kirk W\";i:1;s:19:\"BUSSIERE, Dirksen E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:48:\"Kinase and phosphatase drug discovery and design\";s:8:\"\u0000*\u0000title\";s:81:\"Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"33\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612043452668\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:81:\"Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1105\";s:8:\"\u0000*\u0000epage\";s:4:\"1137\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"WAGMAN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Allan S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:15:\"JOHNSON, Kirk W\";i:1;s:19:\"BUSSIERE, Dirksen E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:48:\"Kinase and phosphatase drug discovery and design\";s:8:\"\u0000*\u0000title\";s:81:\"Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"33\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
